CBAY - GlaxoSmithKline And Linerixibat In Cholestasis Pruritus: It Is Worth A Look
Market Assessment
GlaxoSmithKline plc (GSK) is a large cap ($99B) commercial stage biopharma known for its innovative therapeutics for diverse disease states affecting many organ systems. GSK is not really a household name in reference to therapeutics for viral and non-viral liver diseases. However, its clinical development of linerixibat (formerly GSK2330672) for adult cholestatic pruritus provides a distinct clinical differentiation from other drug candidates currently in clinical trials.
Linerixibat is an Ileal bile acid transporter (IBAT) inhibitor in Phase 2 clinical development for pruritus associated with adult cholestatic liver disease, primary biliary cholangitis ((PBC)). Cholestatic